Allstate Corporation’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.7M | Buy |
127,147
+34,044
| +37% | +$4.77M | 0.19% | 70 |
|
|
2025
Q4 | $11.4M | Buy |
93,103
+47,838
| +106% | +$5.81M | 0.16% | 92 |
|
|
2025
Q3 | $5.02M | Buy |
45,265
+42,683
| +1,653% | +$4.85M | 0.11% | 100 |
|
|
2025
Q2 | $286K | Sell |
2,582
-41,452
| -94% | -$4.41M | 0.02% | 129 |
|
|
2025
Q1 | $4.93M | Buy |
44,034
+6,986
| +19% | +$721K | 0.15% | 86 |
|
|
2024
Q4 | $3.42M | Buy |
+37,048
| New | +$3.34M | 0.1% | 115 |
|
|
2024
Q3 | – | Sell |
-3,656
| Closed | -$251K | – | 159 |
|
|
2024
Q2 | $251K | Sell |
3,656
-593
| -14% | -$39.6K | 0.02% | 182 |
|
|
2024
Q1 | $311K | Buy |
4,249
+187
| +5% | +$14.4K | 0.02% | 169 |
|
|
2023
Q4 | $329K | Buy |
4,062
+183
| +5% | +$14.2K | 0.02% | 152 |
|
|
2023
Q3 | $291K | Hold |
3,879
| – | – | 0.02% | 159 |
|
|
2023
Q2 | $299K | Hold |
3,879
| – | – | 0.02% | 160 |
|
|
2023
Q1 | $322K | Sell |
3,879
-42,667
| -92% | -$3.53M | 0.02% | 142 |
|
|
2022
Q4 | $4M | Buy |
46,546
+748
| +2% | +$59.2K | 0.12% | 116 |
|
|
2022
Q3 | $2.83M | Sell |
45,798
-885
| -2% | -$55.8K | 0.08% | 145 |
|
|
2022
Q2 | $2.88M | Buy |
46,683
+27,842
| +148% | +$1.72M | 0.09% | 139 |
|
|
2022
Q1 | $1.12M | Sell |
18,841
-73,249
| -80% | -$4.68M | 0.03% | 371 |
|
|
2021
Q4 | $6.69M | Buy |
92,090
+79,008
| +604% | +$5.44M | 0.13% | 123 |
|
|
2021
Q3 | $914K | Sell |
13,082
-2,783
| -18% | -$196K | 0.04% | 310 |
|
|
2021
Q2 | $1.09M | Sell |
15,865
-2,472
| -13% | -$165K | 0.04% | 286 |
|
|
2021
Q1 | $1.19M | Buy |
18,337
+9,723
| +113% | +$627K | 0.04% | 271 |
|
|
2020
Q4 | $502K | Sell |
8,614
-7,749
| -47% | -$468K | 0.02% | 515 |
|
|
2020
Q3 | $1.03M | Sell |
16,363
-19,753
| -55% | -$1.37M | 0.03% | 229 |
|
|
2020
Q2 | $2.78M | Buy |
36,116
+2,967
| +9% | +$227K | 0.1% | 79 |
|
|
2020
Q1 | $2.48M | Buy |
33,149
+20,493
| +162% | +$1.42M | 0.1% | 81 |
|
|
2019
Q4 | $822K | Buy |
+12,656
| New | +$824K | 0.01% | 449 |
|
|
2019
Q3 | – | Sell |
-33,225
| Closed | -$2.25M | – | 507 |
|
|
2019
Q2 | $2.25M | Sell |
33,225
-22,035
| -40% | -$1.45M | 0.04% | 263 |
|
|
2019
Q1 | $3.59M | Buy |
55,260
+30,873
| +127% | +$2.05M | 0.1% | 151 |
|
|
2018
Q4 | $1.52M | Buy |
+24,387
| New | +$1.7M | 0.05% | 243 |
|
|
2017
Q3 | – | Sell |
-31,444
| Closed | -$2.23M | – | 120 |
|
|
2017
Q2 | $2.23M | Buy |
+31,444
| New | +$2.09M | 0.12% | 74 |
|
|
2017
Q1 | – | Sell |
-76,442
| Closed | -$5.47M | – | 206 |
|
|
2016
Q4 | $5.47M | Buy |
76,442
+71,950
| +1,602% | +$5.35M | 0.33% | 99 |
|
|
2016
Q3 | $355K | Sell |
4,492
-5,257
| -54% | -$427K | 0.03% | 172 |
|
|
2016
Q2 | $813K | Sell |
9,749
-6,537
| -40% | -$580K | 0.05% | 123 |
|
|
2016
Q1 | $1.5M | Sell |
16,286
-26,678
| -62% | -$2.41M | 0.13% | 117 |
|
|
2015
Q4 | $4.35M | Buy |
+42,964
| New | +$4.47M | 0.41% | 63 |
|
|
2014
Q3 | – | Sell |
-126,500
| Closed | -$10.5M | – | 260 |
|
|
2014
Q2 | $10.5M | Sell |
126,500
-68,979
| -35% | -$5.37M | 0.28% | 123 |
|
|
2014
Q1 | $13.9M | Buy |
+195,479
| New | +$15.3M | 0.45% | 54 |
|
Other funds holding GILD
VCM
VPM
Allstate Corporation's GILD Position: Q1 2026 in Review
Allstate Corporation increased its Gilead Sciences (GILD) stake by 37% in Q1 2026, buying an estimated $4.77M and bringing the position to 127,147 shares worth $17.7M. The position accounts for 0.19% of the portfolio, ranked #70.
Allstate Corporation first reported a position in GILD in Q1 2014 and has held it in 36 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Allstate Corporation held 127,147 shares of Gilead Sciences worth $17.7M as of Q1 2026.
- Allstate Corporation bought 34,044 Gilead Sciences shares in Q1 2026, an estimated $4.77M.
- Gilead Sciences made up 0.19% of Allstate Corporation's portfolio in Q1 2026, its #70 holding.
- Allstate Corporation first reported a position in Gilead Sciences in Q1 2014 and has held it in 36 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Allstate Corporation's 13F filing for Q1 2026, filed 11 May 2026.